Treatment with Verzenio helped people with a common type of early breast cancer liver longer than those given standard ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the primary overall survival (OS) analysis of ...

Eli Lilly (LLY) stock in focus as its antitumor agent Verzenio improves survival in high-risk early breast cancer patients in ...

In the heat of the CDK4/6 market showdown, Eli Lilly has notched an overall survival win to back Verzenio’s case against ...

The 7-year analysis also demonstrated sustained invasive disease-free survival and distant relapse-free survival benefit.

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung ...

Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks to watch as Jim Cramer looked at market rationality. Cramer discussed ...